Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Immunomodulatory agents lenalidomide and pomalidomide co‐stimulate T cells by inducing degradation of T cell repressors I karos and A iolos via modulation of the E 3 ubiquitin ligase complex CRL 4 CRBN2013 · 634 citations
2. 2A Bayesian Case Study in Oncology Phase I Combination Dose-Finding Using Logistic Regression with Covariates2009 · 45 citations
3. 3Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group2016 · 948 citations
4. 4CC-92480, a Novel Cereblon E3 Ligase Modulator, Is Synergistic with Dexamethasone, Bortezomib, and Daratumumab in Multiple Myeloma2019 · 21 citations
5. 5Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease2021 · 58 citations